Incyte Corporation (INCY) Free Cash Flow CAGR:402.37%(TTM)
Free cash flow CAGR uses precomputed cash-flow statement history.
Over longer horizons, Incyte Corporation's Free Cash Flow CAGR averages 37.27% over 3 years and 20.60% over 5 years.The TTM figure compares the trailing 12 months (sum of the latest four quarters) with the 12 months before that. Rows in the history table compare fiscal years, and the quarterly table compares single quarters; the three measure different windows and will differ. Free cash flow CAGR measures how Incyte Corporation's cash generation has grown. FCF represents the cash available for dividends, buybacks, debt reduction, or reinvestment.
INCY Free Cash Flow CAGR Chart
Incyte Corporation (INCY)
INCY Quarterly Free Cash Flow Growth (YoY)
Free Cash Flow growth vs the same quarter one year earlier, last 20 quarters.
INCY Free Cash Flow CAGR History
| Year | Start FCF | End FCF | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2025 | $249.07M | $1.35B | +$1.11B | +443.87% | +443.87% |
| 2024 | $449.00M | $249.07M | $-199.93M | -44.53% | -44.53% |
| 2023 | $892.11M | $449.00M | $-443.11M | -49.67% | -49.67% |
| 2022 | $568.48M | $892.11M | +$323.63M | +56.93% | +56.93% |
| 2021 | $-311.98M | $568.48M | +$880.46M | N/A | N/A |
| 2020 | $632.59M | $-311.98M | $-944.57M | -149.32% | N/A |
| 2019 | $262.74M | $632.59M | +$369.85M | +140.76% | +140.76% |
| 2018 | $-204.01M | $262.74M | +$466.75M | N/A | N/A |
| 2017 | $184.48M | $-204.01M | $-388.49M | -210.59% | N/A |
| 2016 | $60.53M | $184.48M | +$123.95M | +204.76% | +204.76% |
| 2015 | $-1.62M | $60.53M | +$62.15M | N/A | N/A |
| 2014 | $4.91M | $-1.62M | $-6.53M | -132.97% | N/A |
| 2013 | $-97.67M | $4.91M | +$102.58M | N/A | N/A |
| 2012 | $-165.51M | $-97.67M | +$67.84M | N/A | N/A |
| 2011 | $93.83M | $-165.51M | $-259.34M | -276.40% | N/A |
| 2010 | $11.97M | $93.83M | +$81.86M | +683.80% | +683.80% |
| 2009 | $-141.56M | $11.97M | +$153.53M | N/A | N/A |
| 2008 | $-93.85M | $-141.56M | $-47.71M | N/A | N/A |
| 2007 | $-51.94M | $-93.85M | $-41.91M | N/A | N/A |
| 2006 | $-103.50M | $-51.94M | +$51.57M | N/A | N/A |
| 2005 | $-116.06M | $-103.50M | +$12.55M | N/A | N/A |
| 2004 | $-128.07M | $-116.06M | +$12.01M | N/A | N/A |
| 2003 | $-70.16M | $-128.07M | $-57.91M | N/A | N/A |
| 2002 | $-59.92M | $-70.16M | $-10.23M | N/A | N/A |
| 2001 | $-103.72M | $-59.92M | +$43.80M | N/A | N/A |
| 2000 | $-56.20M | $-103.72M | $-47.52M | N/A | N/A |
| 1999 | $1.50M | $-56.20M | $-57.70M | -3846.67% | N/A |
| 1998 | $-7.40M | $1.50M | +$8.90M | N/A | N/A |
| 1997 | $-4.20M | $-7.40M | $-3.20M | N/A | N/A |
Quarterly Free Cash Flow: QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q1 2026 | $359.15M | -31.1% | +36.6% |
| Q4 2025 | $521.42M | -4.3% | +43.3% |
| Q3 2025 | $544.64M | +2022.0% | +85.8% |
| Q2 2025 | $25.67M | -90.2% | — |
| Q1 2025 | $262.90M | -27.7% | +25.6% |
| Q4 2024 | $363.83M | +24.1% | +150.1% |
| Q3 2024 | $293.18M | — | +114.2% |
| Q2 2024 | -$631.11M | — | — |
| Q1 2024 | $209.26M | +43.9% | — |
| Q4 2023 | $145.46M | +6.3% | -44.6% |
| Q3 2023 | $136.86M | -54.3% | -49.0% |
| Q2 2023 | $299.19M | — | +84.2% |
| Q1 2023 | -$132.51M | — | — |
| Q4 2022 | $262.39M | -2.3% | +224.4% |
| Q3 2022 | $268.57M | +65.4% | +20.5% |
| Q2 2022 | $162.41M | -18.3% | +52.3% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About Incyte Corporation
Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's pipeline features several promising candidates. Among its clinical-stage assets are ruxolitinib, targeting steroid-refractory chronic graft-versus-host disease (GVHD), and itacitinib, which is undergoing Phase II/III trials for newly diagnosed chronic GVHD. Pemigatinib is also being investigated for conditions such as bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and other tumor types. Further advancing its research, the company is developing Parsaclisib, currently in Phase II studies for follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma. Additionally, Retifanlimab is in Phase II development for multiple indications, including MSI-high endometrial cancer, Merkel cell carcinoma, anal cancer, and non-small cell lung cancer. Incyte maintains a broad network of strategic alliances with numerous pharmaceutical and biotech companies, including key partners like Novartis International Pharmaceutical Ltd., Eli Lilly and Company, and Agenus Inc., among many others. These collaborations extend to clinical trials, notably joint efforts with MorphoSys AG and Xencor, Inc., to evaluate a combination therapy involving tafasitamab, plamotamab, and lenalidomide for patients with recurrent or resistant diffuse large B-cell lymphoma and follicular lymphoma. Established in 1991, the corporation's main offices are situated in Wilmington, Delaware.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- William J. Meury